Real Talk: CBD’s Limitations

supermarket aisle with many products

There’s no avoiding CBD these days — it’s everywhere you look. The once-obscure non-intoxicating cannabinoid is being added to every conceivable product: CBD mascara, hair gel, even hamburgers. It can be purchased at CVS and Walgreens.

And perhaps that’s the problem. CBD has been sanitized, presented as the “non-psychoactive” (it is psychoactive in fact, just not intoxicating) or “medicinal” cannabinoid, solely to differentiate it from THC and its illicit association with the pre-legalization market. For those of us who have been promoting cannabis therapies for many years, the faddish rise of CBD can be irksome. Not because CBD doesn’t deserve the attention, but because it’s disrespectful to the plant to claim that we can get all the benefits of cannabis — and none of the stigma — from a single cannabinoid. No single ingredient, cannabis-derived or not, could ever hope to deliver on all the promises marketers are making on CBD’s behalf. CBD is an amazing cannabinoid with a wide range of applications, but it is no panacea — because there is no panacea. Especially since of the cannabinoids we know, CBD is one of the least effective in isolation.

BACK TO BASICS

In the natural plant, CBD exists alongside hundreds if not thousands of other plant-produced compounds called phytochemicals. All cannabinoids benefit from being delivered in their native phytochemical complex–a phenomenon called the Entourage Effect–but CBD in particular craves the synergistic presence of other cannabinoids, terpenes and flavonoids. It is a weak antagonist of both cannabinoid receptors (CB1 and CB2), meaning it decreases reuptake of certain neurotransmitters in a mechanism similar to how SSRI antidepressants affect serotonin. CBD’s effects are broader than they are deep: it interacts with a wide range of neurotransmitters, but the effect is generally mild, and relies heavily on the supporting effects of its fellow cannabinoids.

Due to its weak activity, CBD must be used in higher potencies to be effective. Unfortunately, many of the products on the shelves have low potency, no listed potency, or use inaccurate testing. A recent study showed that over 70% of CBD products were inaccurately labeled, and 26% were overlabeled, e.g. the product contained negligible amounts of CBD. The study had flaws, but it made it clear that the current state of CBD labeling is buyer-beware.

NOT FOR EVERY PRODUCT

There are also a number of products in which the inclusion of CBD is a total waste. In order to interact with the body’s cannabinoid receptors, CBD has to be ingested or sit on the skin for a significant period of time – usually upwards of 15 minutes. Products such as hair pomade (there are no CB receptors in our hair) or body wash (rinses right down the drain) are capitalizing on the marketing force of CBD rather than delivering meaningful improvements.

CBD is showing incredible clinical promise as an anti-inflammatory, antispasmodic, and recently, as an antibiotic. We owe it to this wonderful chemical to be honest about what it can’t do, so that our customers believe us when we tell them what it can.

Summer Recipes: Jell-O Shots and Ice Pops

red popsicles

SōRSE can be warmed up or frozen for any seasonal treat! Check out a few recipes our product designer whipped up for the 4th!

CHERRY COLA JELL-O SHOTS

Approximately 15 cubes; 20 mg of CBD per cube 

Ingredients:

  • 3 packages of 6oz cherry Jell-O
  • 1 cup Water
  • 1 gram liquid SōRSE
  • 2.75 cups Cherry Cola

Directions:

  • Boil water and Cherry Cola together.
  • Using a whisk, dissolve gelatin into boiling mixture until all granules are dissolved.
  • Whisk in liquid SōRSE until evenly incorporated.
  • Spray shallow 4 x 8 inch dish with Pam, canola, or coconut oil spray.
  • Pour mixture into dish and chill in refrigerator for at least four hours.
  • Once set, dip dish bottom into hot water to loosen Jell-O from the pan. Slide spatula around edges to loosen sides.
  • Slice into cubes sized approximately 3 x 5 inches each.

RASPBERRY COCONUT ICE POPS

Makes 6 ice pops

Dairy-Free, Vegan; 20 mg of CBD per serving 

Ingredients:

  • 1 cup frozen, defrosted raspberries
  • 5 oz. water
  • 4 tbsp. sugar
  • 14.75 oz. full fat coconut milk
  • .4 grams liquid SōRSE (if needed, use a micro scale to measure out grams)
  • Agave nectar
  • 5 T. sugar

Directions:

  • Heat the water and the sugar over low heat in a small sauce pot until sugar is dissolved.  Cool to room temperature.
  • Process this cooled mixture with the raspberries until smooth.
  • Pour into the molds until halfway full.
  • Heat the second batch of ingredients until sugar is dissolved and no longer grainy.  Cool to room temperature.
  • When the raspberry portion is frozen, fill almost to the top with the coconut portion, but not so much that the inner stick will ooze liquid out when pushed down.
  • Freeze until frozen.

Update: Regulations for New Cannabis Products in Canada

person filling out documents

On June 14, the Government of Canada announced amendments to the Cannabis Regulations setting out the rules governing the legal production and sale of edible cannabis, cannabis extracts and cannabis topicals.

The amended regulations under the Cannabis Act will support our overarching goal of keeping cannabis out of the hands of youth and protecting Canadians by helping to mitigate the health risks posed by these new cannabis products. I encourage adult Canadians who choose to consume cannabis to remember to store it safely out of the reach of children and youth, and to consult the new evidence-based resources on Health Canada’s website that can support you in making informed decisions. –The Honourable Ginette Petitpas Taylor, Minister of Health




We’ve compiled a few key sections of the regulations for you below.

 

WHO DOES THIS APPLY TO?

  • Holders of federally issued licences for cultivation, processing and sale for medical purposes, who are required to provide information to the Minister;
  • Public P/T bodies that are authorized to sell cannabis under a P/T Act, which are required to provide information to the Minister; and
  • Private distributors and retailers, who are required to provide data to the public body authorized to sell cannabis or that authorizes sale under P/T legislation (typically a Crown Corporation or a provincial ministry).

 

LABELING

Amended labeling regulations include:

  • For dried or fresh cannabis and cannabis extracts that are in discrete units and intended to be inhaled or for cannabis extracts that are not in discrete units, THC and CBD concentration must be expressed in milligrams per gram (mg/g).
  • For cannabis extracts that are in discrete units and not intended to be inhaled and for edible cannabis, the quantity of THC and CBD must be expressed in milligrams. In addition, for any cannabis extract in a container with an integrated dispensing mechanism, the quantity of THC and CBD per activation must be indicated in milligrams (mg).
  • For cannabis topicals, the amount of THC and CBD can be expressed as either milligrams per gram (concentration) or milligrams (quantity).

PACKAGING

“The current Regulations allow for one brand element, other than a brand name, to appear on the label of cannabis products, provided that brand element meets certain requirements. One of those requirements is that the surface area of the brand element must be smaller than or equal to the surface area of the standardized cannabis symbol. However, for products containing 10 ppm THC or less, such as pure CBD oil, there is no requirement for the standardized cannabis symbol to appear on the product label. For products with 10 ppm or less, the amended Regulations will specify that the brand element must be smaller than or equal to 25% of the principal display panel, and must be smaller than or equal to the area within the border of the health warning message that appears on the label.

GOOD PRODUCTION REQUIREMENTS

Additions to production requirements have also been added:

  • Requirements that pertain to the cleanliness of equipment used with cannabis or ingredients will be expanded to also include conveyances (in this context, the term “conveyance” refers to anything that is used within the licensed facility to transport cannabis or ingredients used in the production of cannabis products; an example would be a forklift or hand lift), consistent with the SFCR (the requirement would apply to both licensed cultivators and licensed processors).
  • Building on existing air filtration requirements (which were designed to prevent the escape of odours associated with cannabis plants), there will be a new requirement to have a ventilation system (whether natural or mechanical) that provides clean air and removes unclean air that may have a negative impact on the cannabis or ingredients. This new requirement will not apply in areas of a building where cannabis is being cultivated under a cultivation licence. This measure is intended to prevent contamination, and is consistent with measures under the SFCR.
  • Sanitation program requirements will be expanded to explicitly require hand cleaning and sanitizing stations and lavatories on a licensed site, if necessary, to prevent the contamination of cannabis or ingredients. There will also be a new requirement (that will apply to licensed processors only) pertaining to employee clothing, footwear, and protective coverings. Both new requirements are consistent with the SFCR. While current sanitation program requirements under the Regulations do not explicitly include such requirements, it is anticipated that most, if not all, of the new elements already form part of sanitation programs in place at most licensed sites.
  • Existing controls designed to prevent the contamination of cannabis will be expanded to also cover ingredients intended to form part of a cannabis product (licensed processors only).
  • Consistent with the SFCR, licensed processors (that produce edible cannabis or cannabis extracts) will be required to prepare, retain, maintain and implement a written preventive control plan (PCP) to identify and address through effective control measures any potential hazards that pose a risk of contamination for these products. The QAP will be required to sign-off on the PCP prior to its implementation. Furthermore, the PCP will need to include documents that show evidence that the requirements of the PCP have been met.
  • Employees of licensed processors who conduct activities involving edible cannabis (or ingredients used in the production of edible cannabis) will be required to have the necessary competencies and qualifications to carry out their duties, consistent with the SFCR.
  • Currently, the QAP is required to investigate every complaint received in respect of the quality of the cannabis and to take measures to address any identified risk. Under the amended Regulations, the QAP will be required to proactively conduct investigations (or to ensure that such an investigation is conducted on their behalf) if they suspect that cannabis or an ingredient presents a risk of injury to human health or does not meet requirements in Part 5 or Part 6 of the Regulations. If their investigation confirms their suspicions, they must immediately take measures to mitigate any risk. The new requirement, which is adapted from the SFCR, will apply to situations such as where the QAP suspects that an ingredient has been improperly stored, resulting in contamination that presents a risk to human health.
  • Licensed processors will need to ensure that steps are taken so that animals are not able to enter into any building or part of a building where cannabis is being produced. While this requirement is taken from the SFCR, it will apply to all licensed processors (not just those processing edible cannabis). Notwithstanding this requirement, if a licensed processor is also a licensed cultivator, the use of beneficial insects (e.g. lady bugs) in cultivation areas within the same building will continue to be permitted.
  • There will be a requirement that any water (including ice or steam used in the production of a cannabis product) coming into contact with cannabis or an ingredient be potable, unless the water does not present a risk of contamination, consistent with the SFCR. This requirement will apply to licensed processors producing the new classes of cannabis.
  • The amended Regulations will also clarify that holders of an analytical testing or research licence will not automatically be subject to the good production practice requirements set out in Part 5, given that, in general, cannabis handled by these licence holders is not consumed by human beings. Researchers may be required to comply with good production practice requirements as a condition of their licence, depending on the activity they are conducting. For example, a researcher administering cannabis to a human test subject would need to ensure that the cannabis meets quality-control requirements. Holders of an analytical testing licence will still need to use validated methodologies when conducting testing.

ADDITIONAL ADJUSTMENTS

 

  • The proposed prohibition on pressurized containers (e.g. metered-dose inhalers) should not form part of the final Regulations, as pressurized containers are subject to controls to regulate their safety under the Canada Consumer Product Safety Act;
  • That requirements for the display of THC and CBD quantity or concentration on product labels should be standardized, thereby enabling consumers to make more informed decisions about consumption;
  • That it would be easier for consumers, sellers, and law enforcement to determine compliance with the public possession limit of 30 grams of dried cannabis “or equivalent” if the labels on cannabis products indicated the product’s equivalency to 30 grams of dried cannabis; and
  • That the proposed transition period of 6 months for cannabis oil be extended to 12 months, with a view to ensuring continued supply to existing products by registered clients who consume cannabis for medical purposes.

5 Questions to Ask Your CBD Supplier

cannabis products and tinctures

Because CBD and terpenes can now be so easily integrated into food and beverage products with greater stability and consistency, we are almost certain to see a surge of new functional applications and products for retailers to stock their shelves. But before brands rush to create their own CBD-infused product, it’s important to understand how to best work with a supplier. Below are five guiding questions that should lead you to the best possible partnership for your product!

1. Stability: What is stability/shelf life of the emulsion as a stand-alone and in a finished product?

Currently, the highest quality water-soluble emulsion is meeting (and exceeding) food-grade stability testing up to 12 months.


What to confirm:

  • Real-time data. The supplier should provide at least 12 months of real-time stability data for their product, as well as any finished products.

2. Testing: Does your supplier have third-party testing results to confirm the quality of their product?

What to confirm:

  • Request that suppliers provide a Certificate of Analysis (COA) from a third-party testing facility to confirm quality.
  • Verify that the COA is through a third-party, not conducted internally.
  • Never work with a supplier who can’t provide any COA.

3. Food-grade Quality & Safety: what processes have you implemented to maintain food-grade quality and safety?

Since the CBD space is still in its adolescence, it’s important to ensure that the CBD supplier is compliant with all FDA regulations and applying a ‘food science perspective’ to the production procedures. Suppliers who are not taking necessary precautions can be problematic for the longevity, scalability, and success of a brand.

What to confirm:

  • Confirm the supplier can provide all requisite quality documentation. This includes, but is not limited to, COAs, allergen statements, regulatory compliance, third-party audits, etc.
  • A supplier’s facility should be CPMG / FSMA compliant. This is separate and in addition to the product’s food-grade rating.

4. Seamless Integration & Packaging: When does dosing take place in the production process and is there specific packaging required to maximize the shelf-life of the product?

Today, there are emulsion technologies available that allow small and large batch dosing with seamless integration.

  • Determine whether a supplier’s emulsion requires major disruption to existing manufacturing and packaging procedures.
  • Ask if the supplier has technical team members who can work with you directly to develop the best approach to dosing and product development.
  • Packaging does matter and some are better than others for water-soluble emulsion technology in finished goods. Ask about their experience – the successes, as well as the failures.

5. Offerings & Associated Taste & Smell: There’s hype around all forms of CBD – CBD isolate, full spectrum, broad spectrum – how do I know which is best for my product?

Each CBD form impacts the taste, smell, and texture of the finished product. These forms can impact the added ingredients, mainly sugar and flavor additives, and overall nutrition of the finished product.

  • Confirm the suppliers can achieve the desired flavor profile (with or without CBD flavor and aroma presence)

10 Things to Know About CBD

bottle of CBD

10 THINGS TO KNOW ABOUT CBD

Despite the rising popularity of CBD products for a variety of uses, there are still plenty of misconceptions about CBD — and a few surprising facts that consumers may not know.

Sure, it’s science — but there’s no reason to complicate it when it comes to CBD myths. We’re giving it to you straight and short ‘n sweet!


1. CBD IS psychoactive, but it is NOT psychotropic meaning it is not an intoxicating cannabinoid, such as its popular sister, THC.

2. CBD may help treat conditions like pain, insomnia, stress and anxiety.

3. CBD may work better for treating conditions when in the presence of other cannabinoids and/or terpenes

4. CBD will NOT show up in a drug test.

5. CBD is NOT addictive.

6. CBD consumer sales expected to reach $1.8 Billion by 2022 (Statista).

7. CBD is NOT limited to medicinal purposes. Consumers can benefit from the use of CBD and can enjoy sharing it socially/recreationally.

8. FACT: As of January 1, 2018, Olympians can legally consume CBD. However, consumers should be wary of the quality of their CBD as it must contain 0.3% THC or less according to the 2014 Farm Bill.

9. CBD is much less potent than THC at relieving symptoms so consuming CBD in larger doses is common and does not create a sedating effect.

10. CBD products are currently being carried by large national retailers such as Walgreens and CVS.

Takeaways from the First FDA Cannabis Hearing (May 2019)

capitol building in DC

The SōRSE team recently attended the FDA cannabis hearing at the end of May. The hearing resulted in a recognition that the FDA needs to catch up with the present consumer demand. In order to do this, guidelines and pathways for regulation are needed. A timeline for this progress has not been provided. Below are takeaways from our team in key categories:

GENERAL TAKEAWAYS

  • 120 testimonies were heard – each ranging 2-5 minutes. The majority advocated for CBD to be allowed in food and supplements. Some advocated for pharmaceutical pathway only, some advocated for a pathway for animal products and feed, and a small fraction advocated for a complete ban of all cannabis products.
  • Most testimony was anecdotal. Many indicated they will submit more specific data via written comments due 7/2.
  • Lack of data: The FDA maintains there is a lack of scientific data to determine safety, however commenters were split. Some viewed there is adequate credible scientific research including:
    • 2018 WHO CBD report
    • In vivo studies in Humans (between 1973-2010 there were 8 studies cited)
    • Epidiolex Safety Trials
    • A critique of Ewing et al, 2019 (liver toxicity in mice).

    However, many commenters when pressed by FDA panelists to provide specific recommendations agreed that more research and data was needed.

     

    CONSUMER DEMAND

    CONSUMER DEMAND IS STRONG FOR FOOD AND SUPPLEMENT CHANNELS.
    • 26% of American adults have tried CBD in the past two years according to the Jan 2019 Consumer Reports nationally representative survey.
    • Consumers believe CBD is effective to treat the condition for which they were taking it (top conditions: anxiety, relaxation and joint pain).
    • Consumers assume the CBD they are taking is safe.

    ECONOMIC IMPACT

    THE US IS MISSING MARKET SHARE TO OTHER COUNTRIES.
    • In North Carolina, hemp farmers get $30-60K per acre for CBD market versus $700/acre for fiber.
    • China already has 50% of global market share, but issues with low quality and harmful contaminants.
    • There are conflicting laws allowing import, but not domestic production.

    FDA CONCERNS

    AN FDA WORKING GROUP HAS BEEN CREATED TO STUDY SAFETY.
    • Labeling – accuracy & what is required on labels
    • Purity/Contaminants (microbial, toxins, solvents, pesticides, heavy metals, synthetic compounds, THC>0.3%)
    • Manufacturing Quality
    • Dosage/Daily Intake
      • “A dose is not a dose” – Ingestion vs inhalation
    • Potential for harm with Chronic Use
    • Appropriateness for General Population (>2 years old)
    • Appropriateness for Pregnant Women
    • Quantification/measures of effectiveness.

Which Vertus-And-Juice Are You?

Vertus bottles and a pineapple

Welcome to the best new — and easy — cocktail of 2019: Vertus sparkling cannabis drink and juice. Breakfast in bed? Vertus and juice. Fireworks under the stars? Vertus and juice. Mind on your money and money on your mind? Vertus and juice. Laaaaaaaiiidddd baaccckk! You get the idea.

But, one important question remains for you: which Vertus and juice best suits you? Thankfully, we’ve set up this helpful guide to illuminate the possibilities before you. Choose wisely!

Orange

Traditional champagne has gotten a pass for too many years! Orange juice needs more brunch options. So, if you’re someone who loves a glass of this delicious citrus stuff, then take back your orange juice — you brunch revolutionary, you! Say goodbye to traditional champagne and say hello to Vertus bubbly in your fresh-squeezed favorite.

Cranberry

Vertus and cran is for the folks looking for a little pizzazz. It’s for the folks who like to wear pearls or cufflinks when they hit the town. For the folks who like a little romance in their life. Go ahead, pour two and wait for a daring stranger to propose a chat. You might just find your true heart match.

Grapefruit

Vertus and grapefruit is most assuredly for the sensible-minded. The early to bed, early to rise folks who like a bright and shiny morning to get things done. Lawn need mowing before the holidays? Vertus and grapefruit. Have to paint a wall in the apartment? We got you.

Grape

For the playful, late night partiers, there’s Vertus and grape juice. Drop a few sliced fruits to go along with it and you have yourself a deliciously infused sangria that you can sway in your chalice as the music goes on and on into the night. Turn it up and have another round, you’ve earned it!

Pineapple

Vertus and pineapple are for the beach-loving peeps who just want to feel the summer breeze on their faces, the sand between their toes and to read a good book between dips in the waves. Let the sun glisten as the bright beverage combination whisks you away to a foreign land without a grey cloud in the sky.

To find your own bottle of Vertus, check out our product map, then call your closest retailer for availability.  

12 Celebs Who Love CBD As Much As We Do

man wearing a hat labeled 'Famous'

The world is changing. More and more cannabis use is accepted in today’s society. And while people have been using cannabis for years (centuries, really), more and more it’s being more acceptable to toke up. And while there are many advocates on the front lines in the world working to push the cannabis envelope, there are also mainstream folks — actors, musicians, and athletes — helping to normalize cannabis in American and global society. As things continue to change, it’s important to take note of who in the celebrity world is helping the cannabis cause and what their motivations are. Let’s investigate.

The Obvious

Seth Rogan: It’s not hard to imagine a man who made a movie about pot delivery called “Pineapple Express” would endorse CBD. But, Rogan feels strongly about the product due to its benefit for Alzheimer’s.

Snoop Dogg: Duh.

Tommy Chong: He credits CBD oil for helping his recovery from prostate cancer.

The Regal

Whoopi Goldberg: She even sells edibles with her company Whoopi & Maya.

Morgan Freeman: Everyone’s favorite voiceover actor uses CBD to help with his fibromyalgia pain.

Melissa Etheridge: She started using it after being diagnosed with breast cancer.

The Tough

Nate Diaz: After winning a brutal MMA fight, Diaz held a press conference while smoking CBD from a vape pen.

Michael J. Fox: He uses CBD to help with the severe symptoms from Parkinson’s disease. Don’t argue with Michael J. Fox.

Mike Tyson: CBD packs a healthy punch. But not as big as Tyson’s left hook.

The Beautiful

Jennifer Aniston: The actress was known decades ago for smoking weed with then-hubby Brad Pitt.

Alessandra Ambrosio: She’s a Victoria’s Secret model. And she swears by CBD to help with sleeping problems and anxiety.

Rihanna: This goddess of music is open about her cannabis use. No secrets surround this musician’s love for CBD.

ICYMI: Our VP of Science at Smart Kitchen Summit 2018

crowd at an event

In case you missed it, our VP of Science, Scott Riefler was a speaker at Smart Kitchen Summit 2018. This executive summit on the future of food and cooking took place in Seattle on October 8-9th, 2018.

SKS says this about the Summit:

“Reinventing the food, home appliance and kitchen industries takes vision. SKS brings together a roster of all stars to share insights, educate and connect. Meet the CEOs, founders, and visionaries reshaping your industry.”




On October 9th Scott participated in “Edible Cannabis: The New Functional Food?” along with Catherine Lamb, The Spoon; Merril Gilbert, TraceTrust; and Linda Gilbert, BDS Analytics.

Check out this interview by The Spoon featuring our VP of Science, Scott where he coins our new favorite hashtag: #LiftOffTime



This is one of our favorite events that brings science and food together under one roof. We’re excited to see what next year will bring!

Want to meet SōRSE at another event? Sign up for our newsletter today!

Photos via The Spoon

What Cannabis Can Teach Us About Whole Plant Medicine

rainbow colored pill capsules

“Isolating an active constituent from a plant is an affront to nature. It is like taking the intelligence and leaving the wisdom behind.” -Deepak Chopra

Awhile back I posted the above quote on Twitter. I work in the cannabis industry, where whole-plant medicine evangelists are common, and it might fairly be said that I belong among their ranks. The “entourage effect” — the concept that when it comes to cannabinoids, flavonoids, and terpenes “the whole is greater than the sum of its parts” — is widely discussed and lauded, and I have seen enough evidence that I believe it.

But because this is social media, it only took a moment for someone to respond that aspirin, codeine/morphine, taxol, quinine, and digoxin are examples of vital medicines based on isolated chemicals from plants. And this is true. But it is also misses the point.

The scientific method relies on minimizing variables, ideally dealing with only one at a time. This gives us rock-solid data, and for this reason, Western medicine avoids treating disease with whole-plant compounds, preferring a single active ingredient delivered via inert carriers. However, Western science is excruciatingly slow in the face of complexity, particularly when research is politically and financially discouraged. And from cannabis there is massive and growing evidence that complexity can actually enhance and tailor efficacy.

Due to prohibition, cannabis plants have in recent history been bred to maximize THC, their marketable “active ingredient,” at the expense of all other components. However, when completely isolated, THC gives an unpleasant high—anxious and dissociative. Similarly, Marinol, the synthetic version of THC, is notoriously nauseating and ineffective. That’s because in the natural plant secondary cannabinoids, flavonoids, and terpenes serve to ballast the less desirable side effects of THC, and they are present in significant quantities in even the most THC-dominant flower. If the variously amplifying and insulating qualities we call the entourage effect are true for cannabis, could they be true for other plant-inspired medicines as well?

Take a classic plant-derived medicine as an example. Aspirin is acetylsalicylic acid, a synthetic analog of a compound in willow bark called salicin, which has analgesic and anti-inflammatory properties. However, the salicin in willow is present in quantities too low to be effective–aspirin is an order of magnitude stronger than willow bark tincture. But that proportion could easily be adjusted through compounding and, unlike aspirin, willow does not damage the intestinal mucosa. If salicin was delivered at high potency in the presence of native phytochemicals would it be more effective and have fewer side effects? In fact, this study found exactly that.

Or imagine if we bred to maximize the most effective ingredients, as we do with cannabis, but still delivered them in a native phytochemical context?

This is not to say that all synergies would be positive. It is possible that under some circumstances undesirable effects would be heightened and desirable ones muted. I am only encouraging an avenue of thought, and I’m likely not the first to have this idea. Herbal medicine practitioners are already working along these lines. I’m hopeful that the shaded and much winding path cannabis has taken to its present form can inspire new areas of exploration in medicine.

Sources

Differences in receptor binding affinity of several phytocannabinoids do not explain their effects on neural cell cultures. – PubMed – NCBI www.ncbi.nlm.nih.gov Neurotoxicol Teratol. 2014 Nov-Dec;46:49-56. doi: 10.1016/j.ntt.2014.09.003. Epub 2014 Oct 12. Research Support, Non-U.S. Gov’t 
Cannabis with high cannabidiol content is associated with fewer psychotic experiences. – PubMed – NCBI www.ncbi.nlm.nih.govSchizophr Res. 2011 Aug;130(1-3):216-21. doi: 10.1016/j.schres.2011.04.017. Epub 2011 May 17. Research Support, Non-U.S. Gov’t